Skip To Main Content
Coaquira Castro on Muck Rack

Coaquira Castro

As seen in: Frontiers in Immunology
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Coaquira

Contact Coaquira, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Comparative Efficacy and Safety of Tislelizumab in Second-Line Esophageal Squamous Cell Carcinoma: Systematic Literature Review and Simulated Treatment Comparisons | Advances in Therapy

|
By Coaquira Castro, BeOne Medicines
| link.springer.com
Abstract Esophageal squamous cell carcinoma (ESCC) accounts for approximately 90% of all esophageal cancer cases and is associated with poor prognosis. However, recent advancements have transformed the treatment landscape. Tislelizumab, a humanized immunoglobulin G4 (IgG4) anti-programmed cell death protein 1 (PD-1) monoclonal antibody, was developed to overcome resistance mechanisms by minimizing binding to FcγR on macrophages.
Open in Who Shared Issue with article?

Frontiers | Tislelizumab efficacy and safety compared to other anti-PD-1s: a network meta-analysis of first-line therapies for unresectable, locally advanced or metastatic esophageal squamous cell carcinoma

|
By Université de Poitiers, Hyun Ae, Coaquira Castro
| Frontiers in Immunology
SYSTEMATIC REVIEW article Front. Immunol. Sec.
Open in Who Shared Issue with article?
See all 2 articles